Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated in adults for the treatment of BRAF V600 positive unresectable or metastatic melanoma.1,2

Landmark data demonstrate Tafinlar + Mekinist achieves durable overall survival and long-term progression-free survival benefits versus BRAF inhibitor alone that are maintained over 5 years. Treatment with Tafinlar + Mekinist is also associated with an established safety profile.3

Please select an option below to find out more about patient management, or the efficacy and safety profile of Tafinlar + Mekinist for the treatment of BRAF-positive metastatic melanoma.

References

  1. Tafinlar (dabrafenib) Summary of Product Characteristics.
  2. Mekinist (trametinib) Summary of Product Characteristics.
  3. Robert C et al. N Engl J Med. 2019 Aug 15; 381:626–636.
TMC20-C004b May 2020
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]